Administrative and Public LawBanking and Financial Markets LitigationCivil Fraud, Asset Tracing and RecoveryCommercial LitigationCompetition LawConstruction and Engineering DisputesContentious Trusts, Estates and Private Wealth DisputesGroup Action LitigationInsolvency LitigationInsurance and Reinsurance LitigationInternational ArbitrationInvestigations and White Collar CrimeProduct LiabilityProfessional Negligence LitigationToxic Tort and ESG
Founded in 2012, Signature Litigation has grown into one of London’s pre-eminent specialist dispute resolution practices. From the outset, we set out to do things differently: a conflict-free, disputes-only platform designed to give clients the undivided focus and strategic agility that complex, high-stakes matters demand.
FIND OUT MORE
Established in 2017, Signature Litigation's Gibraltar office was founded to address growing demand for specialist expertise in commercial litigation and private wealth disputes on the Rock.
FIND OUT MORE
Signature Litigation AARPI houses one of France’s most enviable product liability practices, with the team also handling commercial and corporate litigation, insurance and reinsurance, toxic tort and ESG, civil fraud and asset tracing, international arbitration, administrative and public law.
FIND OUT MORE
Frankfurt has emerged as one of Europe's foremost financial and commercial centres and, increasingly, as a bridge between European and Asian markets. With that growth comes an increasing demand for sophisticated dispute resolution. Signature Litigation established its Frankfurt office to meet this need, bringing our conflict-free, disputes-only platform to the German market.
FIND OUT MOREPartner Emmanuèle Lutfalla comments on the insurance consequences in relation to a French court’s recent decision regarding backing a class action against French multinational healthcare company Sanofi in the so-called Depakine case. Emmanuèle’s comments were published in La Tribune de L’Assurance, 1 February 2022, here.
Having been accepted by the court of the first instance (Sanofi announcing that it intends to appeal), the group action against the pharmaceutical company is likely to further strain the market for liability claims against drug producers, as Emmanuèle Lutfalla, points out: "On liability, this matter is highly sensitive and could lead to inflationary trends towards insurers and reinsurers, linked to the increasing mobilisation of image protection and crisis management guarantees, as well as a corresponding increase in defence costs. The ceilings of guarantees/limit of liability questions applicable, given the co-existence of a group and individual actions all targeting the same breach, will surely also raise questions about the aggregation/consolidation of individual claims within the framework of group action.”
